• ONWARD Medical reported revenue of €2.5 million for the third quarter of 2026.
• ARCEX systems sold or supplied through paid evaluations totaled 88, up 120% year over year.
• Net cash stood at €73.4 million on September 30, 2026; quarterly cash burn totaled €8.1 million.
• Commercial reach exceeded 170 clinics worldwide, including more than 150 US clinics and Veterans Affairs facilities.
• The Empower BP pivotal trial had enrolled 31 participants, with 16 clinical sites actively recruiting as of November 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONWARD Medical NV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.